VPM
CBIO

Vanguard Portfolio Management’s Crescent Biopharma CBIO Stock Holding History

Vanguard Portfolio Management’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.4M Buy
+188,803
New +$3.69M ﹤0.01% 2560

Other funds holding CBIO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
RCP
Remedium Capital Partners Fort Lauderdale, Florida $452M AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Vanguard Portfolio Management's CBIO Position: Q2 2026 in Review

Vanguard Portfolio Management opened a new position in Crescent Biopharma (CBIO) in Q2 2026: 188,803 shares worth $3.4M. The stake represents ﹤0.01% of the portfolio and ranks #2560 among its holdings.

39 funds tracked by Wall St. Rank hold CBIO as of Q2 2026.

  • Vanguard Portfolio Management held 188,803 shares of Crescent Biopharma worth $3.4M as of Q2 2026.
  • Crescent Biopharma was a new Vanguard Portfolio Management position in Q2 2026.
  • Crescent Biopharma made up ﹤0.01% of Vanguard Portfolio Management's portfolio in Q2 2026, its #2560 holding.
  • 39 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2026.

Based on Vanguard Portfolio Management's 13F filing for Q2 2026, filed 13 Aug 2026.